People · Operator
Named in public records as an officer, director or promoter · active 2008–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Unum Therapeutics Inc. | — | Biotechnology | Series D+ | $220.5M | $4.3B | 2014 |
| Checkmate Pharmaceuticals, Inc. | — | Biotechnology | Series C | $185.1M | $3.5B | 2018 |
| Precision Biosciences Inc | — | Biotechnology | Series C | $153.3M | $1.6B | 2015 |
| Compass Therapeutics LLC | — | Biotechnology | Series D+ | $132.6M | $900.7M | 2015 |
| Ultragenyx Pharmaceutical Inc. | — | Biotechnology | Series C | $108.8M | $3.1B | 2012 |
| LigoCyte Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $50.1M | $68.0M | 2008 |
| Symbiomix Therapeutics, LLC | — | Pharmaceuticals | Series B | $25.5M | $204.0M | 2013 |
| Zero Point Five Therapeutics, Inc. | — | Biotechnology | Series A | $11.5M | $15.7M | 2023 |
| Meves Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $10.9M | $337.8M | 2018 |
Ben Auspitz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ben Auspitz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Rishi Gupta | 2 | 12 |
| Carl Gordon | 1 | 24 |
| JEFF SMITH | 1 | 17 |
| Michael Powell | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Robert Weisskoff | 1 | 12 |
| Bruce Booth | 1 | 12 |
| Stephen Squinto | 1 | 8 |
| Errik Anderson | 1 | 8 |
| Thomas Beck | 1 | 7 |
| Ivor Royston | 1 | 7 |
| Philip J. Ferneau | 1 | 6 |
| Klaus Veitinger | 1 | 6 |
| Philip Ferneau | 1 | 6 |
| Alan Fuhrman | 1 | 5 |
| Charles Wilson | 1 | 5 |
| Robert Adelman | 1 | 5 |
| Keith Flaherty | 1 | 5 |
| C. Boyd Clarke | 1 | 4 |
| MATTHEW KANE | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.